晚期或转移性平滑肌肉瘤临床试验疗效阈值:EORTC软组织与骨肉瘤组基于文献综述的荟萃分析
该荟萃分析基于2003-2018年PubMed文献,纳入47项研究、约1500例晚期或转移性平滑肌肉瘤患者,采用随机效应模型分别汇总一线和后线试验的3个月和6个月无进展生存率。一线患者PFSR-3m为74%、PFSR-6m为58%,后线患者分别为48%和28%,推荐与非推荐治疗间无差异,并据此提出未来II期试验的疗效阈值。
要点
- 一线LMS患者汇总PFSR-3m为74%,PFSR-6m为58%。
- 后线LMS患者汇总PFSR-3m为48%,PFSR-6m为28%。
- 推荐与非推荐治疗间PFSR无差异,未来试验可参考新阈值。
核心结论
- 该研究为晚期或转移性平滑肌肉瘤II期试验设计提供了新的疗效基准。
研究设计与样本
- 通过PubMed文献综述(2003-2018年发表,≥10例成人LMS患者)识别临床试验,并对无法从发表文献中获取的估计值发送数据请求。
- 从47项研究中获得7项一线和16项后线试验的信息,共纳入1500例LMS患者。
- 采用随机效应荟萃分析分别汇总一线和后线患者的试验特异性估计值,并按ESMO 2018指南将治疗分类为推荐或非推荐。
主要发现
- 一线患者汇总PFSR-3m为74%(95%CI 64-82%),PFSR-6m为58%(95%CI 50-66%)。
- 后线患者汇总PFSR-3m为48%(95%CI 41-54%),PFSR-6m为28%(95%CI 22-34%)。
- 一线和后线中推荐治疗与非推荐治疗之间未观察到差异。
- 在真实获益为风险比0.65的替代假设下,一线PFSR-6m≥70%可提示药物活性;后线PFSR-3m≥62%或PFSR-6m≥44%可提示药物活性。
- 研究还提供了子宫平滑肌肉瘤的具体结果。
关键数值与推荐
- 一线:在真实获益为风险比0.65的替代假设下,PFSR-6m≥70%可提示药物活性。
- 后线:PFSR-3m≥62%或PFSR-6m≥44%可提示药物活性。
临床怎么用
- 肿瘤内科医生在设计或解读晚期/转移性LMS的II期试验时,可参考一线和后线的PFSR阈值判断药物活性。
- 解读试验结果时需注意推荐与非推荐治疗间PFSR无差异,阈值适用于整体LMS人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2002, the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group reported well-established values for conducting phase II trials for soft-tissue sarcomas. An update is provided for leiomyosarcoma (LMS). MATERIALS AND METHODS: Clinical trials with advanced or metastatic LMS were identified via literature review in PubMed (published 2003-2018, ≥10 adult LMS patients). End-points were 3- and 6-month progression-free survival rates (PFSR-3m and PFSR-6m). When estimates could not be derived from publications, data requests were sent out. Treatments were classified as recommended (R-T) or non-recommended (NR-T) according to the ESMO 2018 guidelines. A random effects meta-analysis was used to pool trial-specific estimates for first-line (1L) or pre-treated (2L+) patients separately. The ESMO Magnitude of Clinical Benefit Scale was used to guide the treatment effect to target in future trials. RESULTS: From 47 studies identified, we obtained information on 7 1L and 16 2L+ trials for 1500 LMS patients. Overall, in 1L, PFSR-3m and PFSR-6m were 74% (95% confidence interval [CI] 64-82%) and 58% (95% CI 50-66%), respectively. For 2L+, PFSR-3m was 48% (95% CI 41-54%), and PFSR-6m was 28% (95% CI 22-34%). No difference was observed between R-T and NR-T for first or later lines. Under the alternative that the true benefit amounts to a hazard ratio of 0.65, a PFSR-6m ≥70% can be considered to suggest drug activity in 1L. For 2L+, a PFSR-3m ≥62% or PFSR-6m ≥44% would suggest drug activity. Specific results are also provided for uterine LMS. CONCLUSIONS: This work provides a new benchmark for designing phase II studies for advanced or metastatic LMS.
引用
- Kantidakis G, Litière S, Neven A, et al. Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. Eur J Cancer. 2021. PMID: 34298376. doi:10.1016/j.ejca.2021.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。